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Abstract
Background: Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder that results in the accumulation
of glycosaminoglycans causing progressive multi-organ dysfunction. Its clinical spectrum is very broad and varies
from the severe Hurler phenotype (MPS I-H) which is characterized by early and progressive central nervous system
(CNS) involvement to the attenuated Scheie phenotype (MPS I-S) with no CNS involvement. Indication, optimal
timing, safety and efficacy of the two available treatment options for MPS I, enzyme replacement therapy (ERT) and
hematopoietic stem cell transplantation (HSCT), are subject to continuing debate. A European consensus procedure
was organized to reach consensus about the use of these two treatment strategies.
Methods: A panel of specialists, including 8 specialists for metabolic disorders and 7 bone marrow transplant
physicians, all with acknowledged expertise in MPS I, participated in a modified Delphi process to develop
consensus-based statements on MPS I treatment. Fifteen MPS I case histories were used to initiate the discussion
and to anchor decisions around either treatment mode. Before and at the meeting all experts gave their opinion
on the cases (YES/NO transplantation) and reasons for their decisions were collected. A set of draft statements on
MPS I treatment options composed by a planning committee were discussed and revised during the meeting until
full consensus.
Results: Full consensus was reached on several important issues, including the following: 1) The preferred
treatment for patients with MPS I-H diagnosed before age 2.5 yrs is HSCT; 2) In individual patients with an
intermediate phenotype HSCT may be considered if there is a suitable donor. However, there are no data on
efficacy of HSCT in patients with this phenotype; 3) All MPS I patients including those who have not been
transplanted or whose graft has failed may benefit significantly from ERT; 4) ERT should be started at diagnosis and
may be of value in patients awaiting HSCT.
Conclusions: This multidisciplinary consensus procedure yielded consensus on the main issues related to
therapeutic choices and research for MPS I. This is an important step towards an international, collaborative
approach, the only way to obtain useful evidence in rare diseases.
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Mucopolysaccharidosis type I (MPS I) is a lysosomal
storage disorder caused by a deficiency of the enzyme
a-L-iduronidase (IDUA) [1] and has an estimated preva-
lence of 0.69 to 3.8 per 100,000 live births [2,3]. Inheri-
tance is autosomal recessive and more than 100
different mutations in the IDUA gene have been
described [4]. Reduced or absent IDUA activity results
in accumulation of the glycosaminoglycans (GAGs)
heparan and dermatan sulfate throughout the body
which leads to widespread cellular, tissue, and organ
dysfunction, and thus progressive disease.
Historically, MPS I is delineated into three disease
phenotypes based on clinical presentation: MPS I-H
(Hurler syndrome, severe phenotype), MPS I-H/S (Hur-
ler-Scheie syndrome, intermediate phenotype) and MPS
I-S (Scheie syndrome, attenuated phenotype). Patients
with MPS I-H have an early-onset, rapidly progressive
disease with CNS involvement, which, if left untreated,
results in early death, usually within the first two dec-
ades of life. Patients with MPS I-S have a much slower
disease progression without clinical involvement of the
CNS and with a near normal life expectancy. Other
common MPS I features include coarse facial features,
hepatosplenomegaly, cardiac disease, joint stiffness, ske-
letal deformities and corneal clouding, all with highly
variable severity [1,5].
Currently, the phenotype is recognized as a continu-
ous spectrum, ranging from severe, with progressive
involvement of the central nervous system resulting in
cognitive decline, to attenuated, without clinical involve-
ment of the central nervous system. Delineation of the
different MPS I phenotypes can be difficult and is based
on the age of presentation, rate of progression and the
genotype of the patient [6].
Intravenous enzyme replacement therapy (ERT) with
laronidase (recombinant IDUA, Aldurazyme
®)h a sp r o -
ven to be safe and effective in MPS I patients across a
wide range of ages and disease severity, significantly
ameliorating somatic disease [7-12]. Laronidase is unable
to cross the blood brain barrier in significant quantity,
at least in the recommended dose (100 IU/kg/week)
[13], and will therefore not prevent cognitive decline in
patients with MPS I-H. A recent report showed that
early and higher-dose intravenous ERT can reduce lyso-
somal storage of GAGs in the brain in dogs with MPS I
[14]. However, this has not been studied in humans.
Hematopoietic stem cell transplantation (HSCT) is the
treatment of choice in the more severely affected
patients with CNS involvement. It has been shown to
preserve intellectual development when performed early
in the course of disease [15,16]. Currently, HSCT is con-
sidered to be indicated for MPS I-H patients under the
age of 2 years and with no or only moderate cognitive
impairment (Developmental Quotient (DQ) > 70) [6].
HSCT carries considerable risks for procedure-related
morbidity and mortality. However, in recent years,
transplant related mortality has declined and the rate of
engraftment has improved, resulting in survival rates
with donor cell engraftment of over 90% [17]. In addi-
tion, laronidase is increasingly used as an adjuvant treat-
ment before HSCT to improve the pre-transplant
clinical condition [6,17].
With increasing insight in the efficacy and limitations
of both disease-modifying treatments, it is important to
update guidelines for treatment. Preferably, these guide-
lines are based on high-level empirical evidence. How-
ever, due to the extreme rarity of the disease, until now
only one randomized controlled trial has been per-
formed, which was on the efficacy of laronidase [8]. Effi-
cacy of HSCT in improving clinical outcome has only
been assessed by retrospective analyses of cohorts, and
no trials have been done comparing both treatment
modalities.
In order to update management guidelines, combining
all available published evidence with current expert
knowledge, a European consensus procedure was orga-
nized with the participation of a group of pediatricians
experienced in treatment of patients with MPS I, and
comprising both metabolic specialists and bone marrow
transplant specialists. The goal was to obtain consensus
on crucial issues related to the two different therapeutic
modalities in MPS I in order to provide clinical
guidelines.
Methods
A modified Delphi technique was used. This methodol-
ogy, developed by the Rand Corporation/University of
California, Los Angeles (UCLA) [18], is based on the
original Delphi process [19], which has been widely used
to achieve consensus on a specific issue, and is increas-
ingly used for the development of clinical guidelines
when there is insufficient evidence [20,21].
To initiate the process, a literature review was per-
formed by two members of a planning committee
(MHdR, FAW), to gather the best available published
evidence on ERT and HSCT in MPS I. An electronic
search was conducted using Pubmed and EMBASE to
identify all relevant articles. Criteria used as key words
were: mucopolysaccharidosis I, MPS I, Aldurazyme, Lar-
onidase, alpha-L-iduronidase, enzyme replacement ther-
apy, bone marrow transplantation and hematopoietic
stem cell transplantation.
Secondly, a European expert panel was composed,
consisting of 8 pediatricians for metabolic disorders and
7 bone marrow transplant physicians, all with acknowl-
edged expertise in the field of MPS I treatment and
research. In addition, 15 MPS I case histories were
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(MHdR, FAW), based on existing MPS I patients. The
case histories contained the patients’ age at diagnosis,
signs and symptoms related to MPS I at the time of
diagnosis, the results of relevant diagnostic tests and, if
available, a picture of the patient at the time of diagno-
sis. Genotypes, although they can be used to predict dis-
ease severity in some patients, were not included in the
case histories, and treatment decisions were therefore
based on clinical signs and symptoms. This was done as
the planning committee felt that genotype-phenotype
correlations are still limited, and as there is already full
agreement on the predictive value of a few (nonsense)
mutations. The case histories were chosen to represent
the full range of the MPS I phenotypic spectrum. Age at
diagnosis ranged from 5 months to 9 years.
The 15 MPS I case histories were sent to each of the
panel members (’written’ round 1), who were asked to
give their opinion on the choice of treatment (decid-
ing ‘YES’ or ‘NO’ in favor of HSCT) for each patient
based on their clinical judgment, and to explain their
decision by reporting the most important reasons on
which their decision was based as well as the per-
ceived issues complicating the decision in that parti-
cular case.
Draft statements on MPS I treatment options, based
on the literature review and personal experience, were
composed by members of the planning committee
(FAW, JJB, SAJ, RFW) (Table 1).
Subsequently, the panel members met during a one-
day face-to-face meeting in Amsterdam, the Nether-
lands, chaired by an experienced moderator (MO), not
involved in MPS I treatment. At the start of the meet-
ing, the same 15 MPS I case histories were presented to
the panel members again, yet in a randomly different
order, to determine intra-observer reproducibility (’writ-
ten’ round 2). This time no reasons for, or issues com-
plicating decisions were collected. Intra-observer
reproducibility was quantified by Cohen’s kappa [22].
This is a measure of agreement which corrects for
agreement by chance. Kappa values may vary from 0
(complete disagreement) to 1 (complete agreement).
The interpretation of kappa is arbitrary. Generally, a
kappa value of 0.61-0.80 is considered to denote “good
agreement” [23]. Wilcoxon’s signed rank test was used
to compare the proportions of pediatricians for meta-
bolic disorders and bone marrow transplant physicians
in favor of HSCT per round.
The results of round 1, including the reported issues
used for, or complicating, decision making, were used as
a starting point for subsequent discussion. The most
appropriate treatment modality for each patient was dis-
cussed in detail with a particular focus on areas of con-
troversies. Decisions made in the first round were
compared with the decisions made in the second round.
The aim of this discussion was to gather all relevant
issues related to the decision making processes on treat-
ment decisions (i.e. installing ERT and/or HSCT) in
Table 1 Draft statements composed by the planning committee
Statement
1. All patients should be genotyped at diagnosis as this may help in (future) decision-making on therapeutic strategies.
2. Patients homozygous or compound heterozygous for mutations clearly associated with MPS I-H (e.g. W402X, Q70X) should be referred
for HSCT.
3. Patients diagnosed before the age of 2.5 years based on clinical signs and symptoms compatible with MPS I-H (i.e. early kyphosis and/
or characteristic facial features and/or CNS-involvement) should be referred for HSCT.
4. HSCT is more successful if performed early and should probably be done after the age of 3 months, as soon as a suitable donor is
available.
5. All patients with MPS I should be tested by an experienced child (neuro-)psychologist for developmental quotient at diagnosis. Tests
should be adapted for physical limitations (e.g. auditory or visual handicaps). If there is significant developmental delay (DQ < 70)
before transplant, the outcome of HSCT on final IQ is likely to be limited. Not performing HSCT in these patients should be considered
as an option.
6. There is yet no evidence that HSCT is the optimal treatment for patients with MPS I-H/S and MPS I-S (patients diagnosed on the basis
of first significant clinical signs and symptoms > 2.5 years and a genotype not indicating MPS I-H). A randomized controlled trial should
elucidate if HSCT is the optimal strategy for these patients.
7. All patients that are not transplanted may benefit significantly from ERT.
8. As the efficacy of ERT improves if initiated at an early age, ERT should be started at diagnosis.
9. There is no evidence that a dose other than the recommended dose (100 IU/kg weekly) of alpha-L-iduronidase is superior. A
randomized controlled trial will be the best strategy to elucidate the optimal dose.
10. Patients who will be/are referred for HSCT may benefit from ERT before HSCT as this can improve the clinical condition of the patient.
11. There is no evidence that ERT before HSCT interferes with engraftment.
12. There is no evidence that ERT after a successful HSCT will improve clinical outcome.
These are NOT the final statements (see results).
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cussed and revised until full consensus was reached, and
a treatment algorithm for MPS I patients was composed.
Results
All 15 invited experts participated in ‘written’ round 1 (8
metabolic physicians and 7 bone marrow transplant
physicians), and 14 participated in ‘written’ round 2 (8
metabolic physicians and 6 bone marrow transplant
physicians). Since it was found out later that 2 experts
had both replied to ‘written’ round 1 after ample discus-
sion, their responses were excluded from the results.
Two of the experts (1 metabolic physician and 1 bone
marrow transplant physician) could not attend the face-
to-face meeting, but one of them responded by e-mail
to ‘written’ round 2. 13 experts attended the face-to-face
meeting (7 metabolic physicians and 6 bone marrow
transplant physicians), and responses to ‘written’ round
2w e r eo b t a i n e df r o m1 4e x p e r t s .Af l o wc h a r to ft h e
process is shown in Figure 1.
T h en u m b e ro fe x p e r t si nf a v o ro fH S C Tv a r i e d
between the 15 case histories from 1 to 13 out of 13 in
r o u n d1a n d1t o1 4o u to f1 4i nr o u n d2 .T h em e d i a n
[range] number of experts in favor of HSCT for all
c a s e sw a s7[ 1 - 1 3 ]a n d4[ 1 - 1 4 ]i nr o u n d s1a n d2 ,
respectively (Table 2). The most frequently reported
issues considered ‘important’ or ‘complicating’ for decid-
ing on HSCT are ranked in Tables 3 and 4.
The intra-observer median [range] kappa was 0.73
[0.09 - 1]; 10 physicians had a kappa > 0.70. The pro-
portion of transplant specialists in favor of HSCT (med-
ian 0.7 and 0.5 in rounds 1 and 2, respectively) was
significantly higher than the proportion of metabolic
pediatricians in favor of HSCT (median 0.3 and 0.1 in
rounds 1 and 2, respectively) for all 15 MPS I case his-
tories (p = 0.003 and p = 0.007, respectively).
The discussion and revision of the draft statements,
composed before the meeting by the planning commit-
tee (Table 1) led to full consensus, indicated by expres-
sion of agreement by all participants, on the 9
statements described below. In addition, a treatment
algorithm for patients with a diagnosis of MPS I, modi-
fied from the algorithm presented by Muenzer et al. [6],
was composed on the basis of the final statements (Fig-
ure 2) and first steps towards a collaborative research
agenda were made.
1. Decisions on selection of disease modifying treatment
for a patient with MPS I should be made within a team.
This team should include at least a metabolic physician, a
bone marrow transplant physician and a
neuropsychologist, all with expertise in MPS I
Rationale
As knowledge on indication, optimal timing and efficacy
of the two disease modifying treatment strategies in
MPS I (ERT and HSCT) is subject to continuous
change, and as management decisions involve judgment
calls and preferences, the choice of therapy for any
given patient with MPS I should be discussed by a team
of experts. Only by this dynamic process patients can be
offered an optimal therapeutic strategy (expert
consensus).
2. The genotype should be established at diagnosis in all
patients with MPS I as this may help in decision making
on therapeutic strategies
Rationale
Genotype-phenotype correlations are still limited in
MPS I, except for a small number of mutations which
invariably result in MPS I-H if present in homozygous
or compound heterozygous combination [4], and few
mutations which reliably predict MPS I-S [24]. However,
new reports [25] and accumulating (unpublished) data
from the MPS I Registry, an observational program
designed to collect data of MPS I patients with the pri-
mary purpose to study the clinical onset, symptoms, and
outcomes of these patients [5], show that the predictive
value of the genotype in MPS I may increase substan-
tially in the (near) future (expert consensus). This will
help in forming the decision on the optimal strategy in
individual patients, and may eventually become indis-
pensable for future introduction of newborn screening
for MPS I (expert consensus). As polymorphic variations
within the IDUA gene may modify the expression of
mutations [26], new studies are needed to determine the
role of these polymorphic variations (expert consensus).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 experts agreed to participate: 
- 8 metabolic physicians 
- 7 bone marrow transplant physicians 
'Written' round 1 
Consensus meeting/ 
’written’round 2 
2 experts excluded from 'written' round 1: 
- 1 metabolic physician & 
 1 bone marrow transplant physician (*) 
1 metabolic physician: 
- did not attend the consensus meeting 
- sent results of 'written' round 2 by e-mail 
13 experts attended the consensus 
meeting and participated in ‘written’ 
round 2: 
- 7 metabolic physicians  
- 6 bone marrow transplant physicians 
1 bone marrow transplant physician: 
- did not attend the consensus meeting 
- did not give opinions in ‘written’ round 2 
Figure 1 Flow chart of the consensus process.( * ) T w oe x p e r t s
were excluded from ‘written’ round 1, because the opinions on
their choice of treatment in round 1 were not obtained individually.
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diagnosed before the age of 2.5 years and with
presumed MPS I-H (presence of clinical signs and
symptoms compatible with MPS I-H, i.e. phenotypic
diagnosis based on clinical expertise), and/or
homozygosity or compound heterozygosity for mutations
exclusively associated with the severe phenotype is HSCT
Rationale
ERT is not effective in preventing neurocognitive decline
in patients with MPS I-H, as the recombinant enzyme
will not cross the blood-brain barrier in sufficient
quantity [7-11]. Early treatment by HSCT may preserve
cognition and may ameliorate or prevent several of the
somatic manifestations of the disease [15,16,27-30]. In
addition, recent advances in chemotherapeutic condi-
tioning and donor selection have significantly improved
the outcome of this procedure [29,30]. Therefore, HSCT
is the preferred treatment for patients with MPS I-H.
Since phenotypic variability exists even within the severe
phenotype, the previously set upper age limit of 2 years
for HSCT cannot be used as a strict criterion, and a
limit of ‘2.5 years’ is more justified (expert consensus).
Table 2 Expert opinions given in rounds 1 and 2 (per patient) divided by physician specialty
Round 1 Round 2
Patient ’YES’ for HSCT ’NO’ for HSCT Missing ’YES’ for HSCT ’NO’ for HSCT
MP TP MP TP MP TP MP TP
1. 0274 0284
2. 3442 1373
3. 7600 8600
4. 3442 4343
5. 6610 8600
6. 6511 8600
7. 2551 1274
8. 2551 3452
9. 0175 0185
10.01741 0185
11.0175 0185
12.5422 6422
13.1462 1274
14.1363 0482
15.6511 7511
Median 2452 1373
MP = Metabolic Physician
TP = Transplant Physician.
Table 3 Top 5 most frequently reported important
criteria to choose ‘YES’ or ‘NO’ for HSCT
Important for ‘YES’ for HSCT
1. Developmental delay
1
2. Young age
3. Severe phenotype
4. Kyphosis
5. Likely to benefit
Important for ‘NO’ for HSCT
1. Milder phenotype
2. Older age
3. Normal development
4. Developmental delay
1
5. Mainly joint stiffness/late diagnosis
1 Also stated as ‘low IQ’ or ‘CNS-involvement’.
Table 4 Top 5 most frequently reported complicating
issues to choose ‘YES’ or ‘NO’ for HSCT
Complicating for ‘YES’ for HSCT
1. Developmental delay
1
2. Older age
3. Cardiomyopathy
4. ERT prior to HSCT desirable
5. Uncertain (CNS) prognosis
Complicating for ‘NO’ for HSCT
1. ERT prior to HSCT might improve symptoms
2. Developmental delay
1
3. Long-term course unknown
4. Unknown role for HSCT in milder phenotype
5. Early diagnosis
1 Also stated as ‘low IQ’ or ‘CNS-involvement’.
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performed early, and should be performed as soon as the
somatic condition allows for the procedure
Rationale
There appears to be a time lag between full hematopoie-
tic engraftment and the start of stabilization of cognitive
decline. Early transplantation, before overt developmen-
tal deterioration has become clear, probably allows the
highest chances of better outcome in intellectual func-
tions (expert consensus). A younger age at transplanta-
tion is an individual predictor for higher neutrophil
recovery after HSCT. Also, younger children tend to
receive favorable higher cell doses from the donor graft,
since they are smaller. A shorter interval between diag-
nosis and transplantation positively influences the out-
come [29,30].
5. Children with MPS I and advanced CNS-disease (i.e. DQ
< 70) are less likely to benefit from transplant. There
should however not be an undue reliance on
developmental assessment in young children with MPS I
Rationale
Poor neurological outcome after HSCT is related to
lower IQ/DQ before transplantation [16]. Developmental
delay in an individual child might be related to severe
somatic disease such as joint stiffness, hearing deficits
and visual handicaps. A well-trained neuropsychologist
with experience in testing children with MPS I-H should
take these factors into account when assessing the
developmental level in a patient (expert consensus). The
decision whether to transplant should subsequently be
made by the team (statement 1).
6. In any individual patient with MPS I-H/S and CNS-
involvement, HSCT may be considered if there is a
suitable donor. However, at present there are no data on
the efficacy of HSCT in patients with this phenotype
Rationale
Patients with MPS I-H/S may display symptoms of CNS
involvement of variable severity [5,31]. However, the
long-term risk for progressive CNS-disease in these atte-
nuated patients is not known (expert consensus). Since
transplant related mortality has declined significantly
and as HSCT has been demonstrated to be able to halt
cognitive decline in patients with MPS I-H, HSCT
might also be considered as therapeutic strategy if
patients with MPS I-H/S display progressive neurocog-
nitive involvement, but only if a suitable donor is avail-
able (expert consensus). In order to study potential
benefits of HSCT in patients with MPS I-H/S, data on
the outcome should be collected in a coordinated multi-
centered fashion (expert consensus).
7. All MPS I patients (including those who have not been
transplanted or whose graft has failed) may benefit
significantly from ERT as this will ameliorate several
somatic symptoms of the disease
Rationale
Clinical trials have demonstrated that ERT is safe and
effective in patients with MPS I across a wide range of
ages (young children to adults) and phenotypes (severe
and attenuated) [7-12]. Long-term ERT effectively treats
several somatic signs and symptoms of MPS I, resulting
in improved health-related quality of life (HRQOL)
[9,11].
8. As the efficacy of ERT improves when initiated at an
early age, ERT should be started at diagnosis
Rationale
End organ damage, associated with progressive GAG
accumulation, may worsen and become irreversible in
untreated MPS I patients (expert consensus). Therefore,
initiation of treatment early in the disease course is
likely required to prevent and/or minimize irreversible
damage at least in symptomatic patients (expert consen-
sus). A case history on siblings started on ERT at differ-
ent ages supports this statement [32].
9. Patients who are referred for HSCT may benefit from
ERT before HSCT as this can improve the clinical
condition of the patient
Rationale
T h ec l i n i c a lc o n d i t i o no fap a t i e n ta tt h et i m eo ft r a n s -
plantation will influence the morbidity and mortality of
the HSCT (expert consensus). Since ERT has shown to
result in a significant and relatively rapid improvement
of respiratory and cardiovascular function [7-11], ERT
 
 
Patient diagnosed with MPS I 
(on the basis of clinical signs and symptoms) 
  ≤ 2.5 yrs of age    > 2.5 yrs of age
* 
 ERT 
HSCT
** 
(without delay) 
ERT 
(without delay) 
*HSCT might be considered  
under special circumstances 
**In patients with presumed 
MPS I-H 
Figure 2 Treatment algorithm for MPS I patients.
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It was shown that ERT prior to HSCT is well tolerated
and may significantly improve the pre-transplant condi-
tion in selected patients [33-36]. In addition, there is
evidence that ERT does not negatively influence engraft-
ment [33-36]. However, initiating ERT should not delay
the transplant (expert consensus).
Discussion
This European consensus project was organized to
develop recommendations for decision making on the
two currently available disease-modifying treatment
options for MPS I patients. This is important, because it
concerns a debilitating condition, involves treatment
modalities that are associated with health risks and con-
siderable financial costs, and there is uncertainty among
practitioners on the optimal management strategies in
the various different phenotypic subtypes. We chose a
modified Delphi process to provide a means to combine
the very limited scientific evidence available on this sub-
ject with expert opinion, and reached consensus on 9
key areas for decisions and the underlying rationale for
the guidance statements. To our knowledge, this is the
first consensus project including both pediatricians for
metabolic disorders and bone marrow transplant physi-
cians, all experienced in the treatment of MPS I
patients.
Over the last three decades, more than 500 HSCTs for
children with MPS I-H have been performed worldwide
[17]. In recent years, transplant related mortality has
declined considerably with survival rates exceeding 90%.
Engraftment has improved equally. International guide-
lines, which include the use of unrelated cord blood as
cell source, therapeutic drug monitoring of Busulfan and
short interval between diagnosis and transplantation are
the most important causes for these improvements
[17,29,30]. As a result, HSCT might be considered as a
therapeutic strategy for patients with MPS I-H/S and
progressive neurocognitive involvement (i.e. the more
severe MPS I-H/S phenotype). However, convincing evi-
dence is needed to support the use of HSCT in this sub-
group of MPS I patients. Unfortunately, there is hardly
any knowledge on the natural course of the disease in
patients with the intermediate phenotype. Until such
information becomes available, HSCT in these patients
should only be performed if the risk-benefit ratio is con-
sidered to be favorable and an optimal donor is
available.
Laronidase received marketing approval in the USA
and Europe in 2003. Several clinical trials, including one
randomized controlled trial, have demonstrated its safety
and efficacy for the treatment of non-neurological symp-
toms of the disease [7-11], and currently over 600
patients with MPS I receive or have received laronidase
(data presented at the MPS I Registry International
Board of Advisors meeting, Istanbul, Turkey, August,
2010, from the MPS I Registry, Genzyme Corp., USA).
Treatment with laronidase should be started at diagnosis
in all symptomatic MPS I patients and laronidase may
also improve the pre-transplant condition in patients
who are awaiting HSCT.
There was complete disagreement (7 in favor of
HSCT vs. 6 not in favor of HSCT) on the preferred
treatment strategy in round 1, being HSCT or no
HSCT, in 4 out of the 15 MPS I case histories (Table
2), which underscores the difficulties in choosing the
most appropriate course of action, even among experts.
All these cases were classified as intermediate, MPS I-
H/S, phenotype during the discussion. Despite the initial
differences of opinion between metabolic physicians and
bone marrow transplant physicians on preferred treat-
ment, with transplant physicians more often favoring
HSCT, elicitation and discussion of the underlying
motives and concerns led to full consensus regarding
the final statements and a joint formulation of the ratio-
nale for these statements.
Based on expert experience, the panel reached consen-
sus that the age limit for HSCT should not be set too
low, as considerable preservation of CNS functions may
still be achieved in patients with MPS I-H if a successful
HSCT is done even after 2 years of age. In addition, the
panel agreed that reliable testing of cognitive develop-
ment (DQ/IQ) in young patients with MPS I can be
very difficult due to symptoms of the disease, including
restricted motor performance. The consensus statement
on this issue (statement 5) was therefore formulated
with caution, and DQ/IQ is not included as a criterion
in the algorithm. The algorithm cannot replace clinician
judgment, and team decisions on treatment should
always be considered on a patient by patient basis. Yet,
the issues reported in Tables 3 and 4 will play an impor-
tant role in this process.
All participants agreed that further studies are
needed to create evidence based protocols on the
treatment of MPS I patients in the future. Due to the
extreme rarity of the disease, it is essential to try to
gather further evidence in an international, interdisci-
plinary, collaborative approach. As formulated by the
panel, future research should have a particular focus
on the long-term neurocognitive outcome of patients
with MPS I-H/S, and on the potential role of HSCT in
the treatment of this phenotypic group. With the pro-
spects of newborn screening for MPS I [37], reliable
tools to predict the clinical phenotype in presympto-
matic children are urgently needed. In this respect, a
better understanding of genotype-phenotype correla-
tions in MPS I, including the potential role of modify-
ing polymorphisms [26] and the possible role of
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The consensus procedure did not include discussion
on possible indications for laronidase in MPS I
patients after HSCT. Experience with ERT in these
patients is still very limited [38], and further studies
are needed to elucidate the role of laronidase in this
group.
Conclusions
We conclude that the modified Delphi consensus proce-
dure used to obtain statements on crucial issues related
to decisions on treatment options in newly diagnosed
MPS I patients was instrumental in obtaining 9 impor-
tant consensus statements. Further collaborative studies
will help to optimize the clinical decision making pro-
cess, which will lead to improvements in life expectancy
and quality of life in MPS I patients.
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